CBL-514, the world’s first investigational drug for large-area localized fat reduction, has demonstrated significant efficacy in its second and the last Phase 2b study (CBL-0205) before Phase 3. 54.2% of participants in the CBL-514 group achieved at least 20% fat volume reduction four…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.